Marker Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 26, 2024
MRKR$0.95-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · Additional · · · Total | ||||||||||||||
| · · Common Stock · · Paid- · · Accumulated · · Stockholders’ | ||||||||||||||
| · Shares · Par value · in Capital · Deficit · Equity | ||||||||||||||
| Balance at January 1, 2022 | 8,307,868 | | $8,308 | | $442,095,642 | | $(398,118,355) | | $43,985,595 | |||||
| Issuance of common shares for cash, net | 60,651 | | 61 | | 202,069 | | — | | 202,130 | |||||
| Stock-based compensation | 37,252 | | 37 | | 5,343,969 | | — | | 5,344,006 | |||||
| Net loss | — | | — | | — | | (29,930,694) | | (29,930,694) | |||||
| Balance at December 31, 2022 | 8,405,771 | | | 8,406 | | | 447,641,680 | | | (428,049,049) | | | 19,601,037 | |
| Shares issued pursuant to ATM and Lincoln Park agreements | | 277,834 | | | 277 | | | 1,014,363 | | | — | | | 1,014,640 |
| Issuance of common stock as commitment fee | 180,410 | | | 180 | | | (180) | | | — | | | — | |
| Issuance of common stock from exercise of stock options | | 27,518 | | | 28 | | | 90,450 | | | — | | | 90,478 |
| Stock-based compensation | — | | | — | | | 1,583,202 | | | — | | | 1,583,202 | |
| Net loss | — | | | — | | | — | | | (8,236,814) | | | (8,236,814) | |
| Fractional shares adjustment due to reverse split | | (113) | | | — | | | — | | | — | | | — |
| Balance at December 31, 2023 | 8,891,420 | | | 8,891 | | | 450,329,515 | | | (436,285,863) | | | 14,052,543 | |
On January 26, 2023, the Company effected a one-for-ten (1-for-10) reverse stock split of its common stock. All historical share and per share amounts reflected in this report have been adjusted to reflect the reverse stock split.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.